目的　探讨肝动脉、门静脉双管灌注化疗联合碘油乙醇注射治疗中晚期肝癌临床疗效。　方法　 138例经病理证实的无手术指征的中晚期肝癌患者 ,分为两组进行治疗 :(1)经皮下埋植式药泵经肝动脉和门静脉双插管灌注化疗组 (AVPC组 ) 80例 ;(2 )经皮下埋植式药泵经肝动脉和门静脉双插管灌注化疗联合碘油乙醇注射治疗组 (联合治疗组 ) 5 8例。　结果　AVPC组和联合治疗组的总有效率分别为 12 6 %和 2 5 9% ;治疗后获得二期手术切除率两组分别为 2 5 %和 12 1% ,差异有显著性意义 (P <0 0 5 ) ;治疗后 0 5、1、2年生存率分别为AVPC组 5 6 3%、45 0 %、2 1 2 % ,联合治疗组分别为 81 0 %、6 1 2 %、39 6 % ,两组间差异有显著性意义 (P <0 0 5 ) ,并发症差异无显著性意义。　结论　联合治疗是治疗中晚期肝癌的有效方法 ,效果优于双管灌注化疗 Objective To investigate the clinical effects of hepatic artery and portal vein double infusion chemotherapy combined with lipiodol ethanol in the treatment of advanced liver cancer. Methods One hundred and thirty-eight patients with pathologically confirmed advanced hepatocellular carcinoma without surgical indications were divided into two groups: (1) transcatheter embolization chemotherapy (AVPC group) 80 Cases; (2) Subcutaneous implantable drug pump via hepatic artery and portal vein dual intubation chemotherapy with lipiodol ethanol injection treatment group (combination therapy group) 58 cases. Results The total effective rates of AVPC group and combination group were 12 6% and 25 9% respectively. The second-stage resection rate after treatment was 25% and 12 1%, respectively, with significant difference (P < The survival rates at 0, 1, 2 years after treatment were 56.3%, 45.0% and 21.2% respectively in the AVPC group and 81.0%, 61.2% and 396 %, The difference between the two groups was significant (P <0 05), no significant difference in complications. Conclusions Combination therapy is an effective method for the treatment of advanced hepatocellular carcinoma, which is superior to double-tube chemotherapy